MPL and Thrombocytopenia: Lusutrombopag (LUSU) is an orally active, small‐molecule thrombopoietin receptor agonist licensed for “improvement of thrombocytopenia associated with CLD in patients undergoing an elective invasive procedure,” launched in December 2015 in Japan to treat thrombocytopenia prior to a planned procedure.